Navigation Links
Latest Sleep Disorder Technology Tested With SleepQuest
Date:9/4/2008

SAN CARLOS, Calif., Sept. 4 /PRNewswire/ -- SleepQuest has partnered with ResMed, a leading manufacturer of medical equipment for sleep-disordered breathing, to conduct clinical trials of a new wireless technology used to monitor patients with Obstructive Sleep Apnea from wherever they are sleeping. The technology is intended to more easily provide data that can be used to improve the quality of care for those requiring PAP treatment.

"We take pride in working with companies on the cutting edge of technology," said Robert Koenigsberg, President/CEO of SleepQuest. "We want to deploy that expertise on behalf of our patients."

Employing Bluetooth technology, sleep data transmits instantly from a CPAP or other medical device to SleepQuest's Sleep Care Specialists, allowing them to monitor adherence that can increase treatment efficacy. This improves patient comfort, ensures better compliance, and reduces need for office visits or in-person device adjustments.

A total of 30 SleepQuest sleep apnea patients are currently participating in the trial. These patients report that the technology is easy to use and presents no technical problems, improving patient convenience by reducing the need for office visits to download data.

ResMed selected SleepQuest to lead this initiative because of their proven disease management approach for Obstructive Sleep Apnea and industry-leading treatment compliance rate.

"Ensuring that patients properly manage their condition through nightly CPAP treatment is our main goal," said Cody Parker, Regional Office Manager "Helping ResMed develop this wireless technology will benefit our patients by making CPAP treatment more comfortable and effective."

SleepQuest has found that without continued support and encouragement, many patients stop treatment after a few weeks. Their Continuum of Care program was developed in response: a step-by-step approach to diagnose and treat sleep apnea with thorough clinical and home support. The result is a patient therapy compliance rate of approximately 90%, compared to the industry average of about 50%.

"We are always looking for ways to provide convenient treatment and follow-up care for our patients," Parker said. "Immediate data transfer allows us to serve our patients more efficiently, saving them time and money."

For more than 10 years, SleepQuest has established itself as a leader in home testing and treatment of sleep apnea. To talk to a SleepQuest representative about treating sleep disorders call 800-813-8358 or email contact@sleepquest.com.


'/>"/>
SOURCE SleepQuest
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007
2. UD researchers race ahead with latest spintronics achievement
3. Digital Healthcare Announces Cincinnati Eye Institute is Latest Retasure Reading Center
4. 49th Annual Meeting of the American Society of Hematology Will Feature the Latest Research in Blood Diseases
5. Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3)
6. PacifiCare Capitulates to Latest Patient Revolt
7. Parks Associates Digital Health Analyst to Present Latest Research and Forecasts at ATA Show
8. Carbon nanotube measurements: latest in NIST how-to series
9. Rudd Report Highlights AMDL, Inc.s Latest Business Achievements; Supports 2008 Financial Guidance
10. [video] Jacques Tizabi, CEO of Universal Detection Technology Discusses Latest Purchase Order on WallSt.nets 3-Minute Press Show
11. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
Breaking Biology News(10 mins):